Veraxa Biotech Outlines FDA-Aligned Model Integration Into R&D Strategy
Veraxa Biotech AG detailed its integration of FDA-aligned New Approach Methodologies (NAMs) into its R&D strategy. The company stated this approach could accelerate its BiTAC® Oncology pipeline and significantly reduce animal testing.
Story updates
11:07:19 AM UTC
SquawkNews
VERAXA Biotech AG outlined the rollout of FDA-aligned New Approach Methodologies across preclinical programs, aiming to accelerate clinical advancement and reduce animal testing, including bypassing some NHP tox studies.Material DetailsContext by AI AnalystThis is an R&D process update supporting V…